NxStage(R) Announces Extension of Medisystems Needle Supply and Distribution Agreement

Tuesday July 21, 2009

LAWRENCE, Mass., July 21 /PRNewswire-FirstCall/ — NxStage Medical, Inc. (Nasdaq: NXTM), a leading manufacturer of innovative dialysis products, today announced that its Medisystems subsidiary has extended for three years a supply and distribution agreement with Fenwal, Inc. of Lake Zurich, Ill. Medisystems provides needle sets and assemblies to Fenwal, a global medical technology company focused on improving blood collection, separation, safety and availability for patient care. Medisystems products involved in this agreement include the MasterGuard needle sets with FingerShield&#153 safety technology, the leading worldwide needle-stick prevention device.

Medisystems is delighted to continue its relationship with Fenwal, said Jeffrey H. Burbank, Chief Executive Officer of NxStage Medical. This agreement provides further validation of our ability to continue to drive steady growth in end-user demand with Medisystems’ innovative, high quality, value added product offerings.

MasterGuard Anti-Stick Needle Protector is the only guarded pheresis needle proven to reduce needlestick injuries, as compared to conventional, unguarded needles. Medisystems’ patented FingerShield technology helps protect medical technicians’ and caregivers’ pressure-holding fingers during pheresis procedures. MasterGuard is also designed to allow for optimal visualization of the needle and does not interfere with site selection, cannulation technique or tapedown for patient safety and procedural efficacy during pheresis.

About NxStage Medical

NxStage Medical, Inc. (Nasdaq: NXTM) is a medical device company, headquartered in Lawrence, Massachusetts, USA, that develops, manufactures and markets innovative products for the treatment of End Stage Renal Disease (ESRD) and acute kidney failure. Medisystems, a wholly owned subsidiary of NxStage, designs, manufactures, imports and distributes innovative medical devices, primarily for use in dialysis and related blood treatments (www.medisystems.com). For more information on NxStage and its products, please visit the company’s website at http://www.nxstage.com.

Forward-Looking Statements

This release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. All statements contained in this release that are not clearly historical in nature are forward-looking, and the words anticipate, believe, expect, estimate, plan, and similar expressions are generally intended to identify forward-looking statements. Actual results may differ materially from those indicated by these forward-looking statements as a result of various important factors including factors that are discussed in NxStage’s filings with the Securities and Exchange Commission, including the Quarterly Report on Form 10-Q for the quarter ended March 31, 2009. NxStage is under no obligation to (and expressly disclaims any such obligation to) update or alter its forward-looking statements, whether as a result of new information, future events or otherwise.

SOURCE NxStage Medical, Inc.

CONTACT:
Kristen K. Sheppard, Esq.
VP, Investor Relations of NxStage Medical, Inc.
+1-978-332-5923
ksheppard@nxstage.com
Web Site: http://www.nxstage.com